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Objectives: Metastatic melanoma has a poor prognosis with 10 year survival 
being < 5%. Standard therapy is the effective but costly Ipilimumab. An emerging 
1st line treatment is Tumor Infiltrating Lymphocytes (TIL), with response rates 
> 50% and expected survival rates of 25%-42% versus 45% (1yr) and 23,5% (2yr) for 
Ipilimumab. TIL is highly personalized, however complex and requests substantial 
upfront investments from the hospital in expensive lab-equipment, staff expertise 
and training, as well as extremely tight hospital logistics. Therefore, an early health 
economic modelling study, supporting a Coverage with Evidence Development (CED) 
program, was performed. MethOds: We used a Markov decision model to estimate 
the expected costs and outcomes (quality adjusted life years; QALYs) for TIL ver-
sus Ipilimumab in metastatic melanoma patients from a societal perspective over 
a life long time horizon. Three mutually exclusive health states (stable disease, 
progressive disease and death) were modelled, divided in first and second line 
treatment. Technical failures and non-compliance were incorporated to reflect the 
dynamic nature of the technology. To inform further research prioritization, Value 
of Information (VOI) analysis was performed. Results: TIL is expected to yield 
more QALYs compared to Ipilimumab (0.99 vs 0.52 respectively) at lower total costs 
(€ 83,588 vs € 87,834 respectively). Based on current information TIL has a probability 
of 88% for being cost effective at a cost/QALY threshold of € 30,000. Expected Value of 
Perfect Information (EVPI) amounted to € 1,2 million. Partial EVPI (EVPPI) was highest 
for survival data (€ 550,000). Expected Value of Sample information was estimated 
€ 355,000 for an optimal sample size of n= 50. cOnclusiOns: TIL is expected to 
improve QALYs compared to Ipilimumab at lower incremental cost and has the 
highest probability of being cost-effective. To reduce decision uncertainty, a future 
clinical trial to investigate survival seems most valuable, and should preferably be 
undertaken as part of a CED program.
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Objectives: This study assessed the cost-effectiveness of everolimus versus axi-
tinib for the treatment of advanced metastatic renal cell carcinoma (mRCC) in the 
United Kingdom (UK). MethOds: A Markov model was developed with three health 
states: stable disease, disease progression and death. The model time horizon was 
12 years and a UK NHS perspective was considered. There are no head to head stud-
ies comparing everolimus with axitinib, thus evidence from a weighted adjusted 
indirect analysis based on the RECORD-1 and AXIS trials was used to compare 
progression-free survival (PFS) for everolimus versus axitinib. Survival distributions 
for PFS were fitted to the post-matched population and fit statistics were generated. 
As overall survival (OS) data were not available from the AXIS trial at the time of 
the indirect analysis, the model assumed that the OS for axitinib was equivalent 
to that of everolimus, based on OS from the RECORD-1 trial. The Weibull survival 
distribution was used for both PFS and OS. Quality of life data were derived from 
the Swinburn et al. study and drug costs were obtained from the British National 
Formulary. Results: Everolimus resulted in a progression-free life expectancy 
of 0.60 years compared to 0.57 with axitinib. Everolimus resulted in 0.65 QALYs 
compared to 0.63 QALYs for axitinib. Active drug costs were £8,105 for everolimus 
and £25,723 for axitinib. Total costs were higher for axitinib (£42,533) compared 
to everolimus (£24,387). The cost difference reflects the higher treatment costs 
per month and longer treatment duration for axitinib compared to everolimus. 
Therefore, the incremental cost of axitinib compared with axitinib was -£18,146, 
highlighting that everolimus is less expensive. The incremental cost per QALY 
gained was -£1,048,954. cOnclusiOns: This cost-effectiveness analysis demon-
strates that everolimus likely dominates axitinib, i.e. it is more effective and less 
expensive compared with axitinib in the treatment of mRCC.
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Objectives: To conduct an economic evaluation comparing Herceptin subcu-
taneous formulation (Herceptin-SC) with -Herceptin intravenous formulation 
(Herceptin-IV), in the treatment of patients with human epidermal growth factor 
receptor 2-positive (HER2+) early and metastatic breast cancer (EBC-MBC), in the 
Greek health care setting. MethOds: A cost-minimization model was developed 
to compare the total cost of care, from the hospital perspective, for new and existing 
patients, over 18 cycles therapy course. Total cost of therapy reflects drug acquisition 
cost, consumables dispensed, hospital overheads, physician and other staff time. 
Costing data were obtained from official Government sources (in 2014) and resource 
utilization data from a local validation of an international time and motion study. 
Due to the short time horizon of the study, costs were not discounted. Results: 
The mean total cost of therapy per patient on Herceptin-IV was estimated at 
€ 24,163 compared to € 23,042 per patient receiving Herceptin-SC. Drug acquisition 
costs accounted for € 22,630 and € 22,579 of total therapy costs for Herceptin-IV and 
Herceptin-SC, respectively. Following drug acquisition costs, the administration cost 
was € 518 and € 161 for Herceptin-IV and Herceptin-SC, respectively. Moreover, the 
central venous access device cost was € 290 and € 0 of the total costs of Herceptin 
IV and Herceptin SC, respectively. Finally, overhead costs made up approximately 
€ 725 of the total cost for Herceptin-IV and € 302 for Herceptin-SC. Sensitivity analy-
sis showed that the results of the model were sensitive to drug acquisition costs 
and patient weight. cOnclusiOns: The cost of treatment with Herceptin-SC is 
assumed equal for everolimus, while utilities for the post progression stages were 
obtained from the literature. Resource use was determined by a panel of five expe-
rienced experts to reflect Portuguese clinical practice. Official unit costs were used, 
following the Portuguese National Health Service perspective. The model adopted 
a lifetime frame (15 years) with a 5%discount rate. Results: Axitinib allowed an 
increment of 0.20 years of progression free survival, 0.53 years of overall survival, 
and 0.32 quality adjusted life years compared to everolimus. Despite having a similar 
daily cost, the use of axitinib implied an incremental cost of 9,100€ , mainly due to 
the increase in progression free survival, that matches second line treatment dura-
tion. Consequently the cost per quality adjusted life year was 28,598€ . Sensitivity 
analyses showed that results were robust to model parameters specification, 
with the main uncertainty source being clinical efficacy. cOnclusiOns: Axitinib 
increased progression free and overall survival, which allowed patients to benefit 
from more quality adjusted life years at a cost increase. Overall, it was possible to 
advocate that axitinib is cost-effective, as the cost per QALY is below commonly 
accepted thresholds.
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Objectives: Clinical studies have shown that docetaxel to be superior to paclitaxel 
in overall survival (OS) and progression free survival (PFS) (median OS: 1.28 vs 1.06 
year; median PFS: 0.47 vs 0.30 year) for the treatment of patients with metastatic 
breast cancer progressing after an anthracycline-based regimen. Other studies 
have shown paclitaxel-albumin extended OS by 9.7 weeks, and TTP by 4 weeks. An 
economic evaluation based on these two clinical trials was performed to compare 
paclitaxel albumin, paclitaxel, and docetaxel as a second line treatment for meta-
static breast cancer. MethOds: A Markov model was conducted using three health 
states: PFS, progressed, and death to estimate overall survival, cost, life year gain 
(LYG) and quality adjusted life year (QALY). Efficacy data for the treatments were 
obtained from the published literature. In the absence of head-to-head trials, com-
parative efficacy and safety of taxanes were estimated using indirect comparisons. 
A 3% discount rate for cost and outcomes was used. Cost of chemotherapy, admin-
istering, monitoring the disease, loss of productivity, and adverse drug reactions for 
patients on treatment were included from the US societal perspective. Results: 
Compared to docetaxel, paclitaxel albumin was found to be less expensive ($36,241 
vs $73,510) and more effective in term of QALYs (0.782 vs 0.710). The incremental cost 
effectiveness ratio (ICER) for paclitaxel albumin compared to paclitaxel was $77,670/
QALY. The probabilistic sensitivity analysis showed that paclitaxel albumin has 70% 
probability of being cost effective at $100,000/QALY threshold value. cOnclusiOns: 
Paclitaxel-albumin is an attractive treatment option for the treatment of metastatic 
breast cancer in patients who have failed 1st-line treatment for metastatic disease. 
The primary analysis comparing paclitaxel albumin to docetaxel demonstrated 
that paclitaxel albumin dominated docetaxel because it was less costly and more 
effective.
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Objectives: Whole-breast external beam radiotherapy (EBRT) is normally given 
over 3-6 weeks after lumpectomy in early breast cancer patients to reduce recur-
rence and mortality. An individualised risk-adapted approach to adjuvant radiother-
apy has been tested in the randomised TARGIT-A trial which tested the efficacy of 
one dose of radiation to tumour bed during lumpectomy. The objective of the present 
study was to assess the cost effectiveness of TARGIT-A in these patients. MethOds: 
A model based economic evaluation compared single dose TARGIT-A with current 
practice of EBRT in UK. A state transition Markov model approach was used to 
simulate the treatment outcomes in a time horizon of 20 years post-surgery. The 
primary outcome of interest was quality adjusted life years gained (QALY) and 
analysis was conducted from the health care payer’s perspective. To address deci-
sion uncertainty, probabilistic sensitivity analysis was performed. A discount rate 
of 3.5% was applied to future costs and effects. Results: In the Base Case Analysis 
TARGIT-A was a dominant strategy yielding higher QALYs at a lower cost than EBRT. 
Discounted EBRT and IORT costs for the time horizon of 20 years were £ 20,926 and £ 
14,461 respectively. Discounted incremental QALY gained by use of IORT was 0.0069. 
Model results were robust to parameter uncertainty and probabilistic results were 
similar to the deterministic results. Application of the net monetary benefit (NMB) 
framework revealed higher NMB for TARGIT-A in all Monte Carlo simulations. Cost 
effectiveness acceptability curves show that TARGIT-A is cost effective at various 
willingness to pay thresholds. cOnclusiOns: TARGIT-A is a cost effective strat-
egy to treat early breast cancer patients in the UK. Implementation of this one-off 
radiation treatment within a risk-adapted approach could improve quality of life 
by sparing them from the protracted course of EBRT, improve compliance, prevent 
unnecessary mastectomies and save valuable NHS resources.
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and capecitabine monotherapy in terms of incidence of diarrhea, vomiting, sto-
matitis/mucositis. The hand-foot syndrome occurrred in less than 5% in case of 
tegafur. Tegafur (in monotherapy or in combination with calcium folinate) is less 
costly than capecitabine. The difference in costs in favor of tegafur monotherapy 
amounted to € 1,956.97 per 1 patient per 6 months or € 3,778.53 per year; of tegafur + 
calcium folinate - € 2,168.12 and € 4,220.06 per 1 patient per 6 and 12 months, respec-
tively. cOnclusiOns: Tegafur is a cost-saving option compared with capecitabine 
with similar efficacy and safety.
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Objectives: There is new RCT phase 3 clinical evidence that bendamustin-
rituximab (B-R) is more effective in terms of progression free survival compared 
to the standard of care CHOP-rituximab (CHOP-R) in indolent non-Hodgkin lym-
phoma (iNHL). Based on this RCT, we performed a cost-utility analysis of B-R com-
pared to CHOP-R in the treatment of follicular iNHL (stage III and IV) in the Czech 
Republic. MethOds: We developed a life-time Markov cohort model with 28-day 
cycle length and 5 health states, i.e. on treatment, rituximab maintenance (R-M), 
stable disease, progression and death. Additionally, we modeled adverse effects 
of treatment and four sub-states during progression (observation, imunochemo-
therapy, R-M, post R-M). Transition probabilities and utilities were derived from 
published literature. Resource use (costs) was calculated from health care payer’s 
perspective in cooperation with major Czech hemato-oncologic experts. Costs and 
outcomes were discounted by 3.5%. Probabilistic sensitivity analysis (PSA) with 
1000 iterations using a willingness to pay (WTP) threshold equal to 3 times GDP per 
capita (40 100 EUR) in the Czech Republic was performed. Results: Over a life-time 
horizon, B-R compared to CHOP-R brings additional 1.21 QALY (7.47 vs. 6.26) and 1.31 
LYG (9.74 vs. 8.43). The incremental total costs were 1,368 EUR (total life time costs 
for B-R and CHOP-R were 43,080 EUR and 41,712 EUR, respectively). ICERs thus equal 
to 1,133 EUR/QALY and 1,044 EUR/LYG. The results of the PSA show that B-R is cost-
effective in 100% iterations under the WTP threshold; and simultaneously in 99.3% 
iterations is cost-effective while using threshold equal to 7,300 EUR. cOnclusiOns: 
B-R proved that it is a highly cost-effective therapy in patients with follicular iNHL. 
The higher costs of initial bendamustin treatment are in the long-term horizon 
offset by substantial savings of progression costs. There is 100% probability of B-R 
being cost-effective at the selected WTP threshold.
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Objectives: The inhibition of epidermal growth factor receptor (EGFR) signaling 
pathway by innovative therapeutics presents promising upshots in oncology. Our 
study aims to quantify first-line treatment with afatinib, an irreversible tyrosine 
kinase inhibitor, compared to pemetrexed+cisplatin (pem+cis), for patients with met-
astatic lung adenocarcinoma harboring common EGFR mutations (DEL19 or L858R) in 
the Netherlands. MethOds: An area under the curve partitioned survival model, con-
structed to quantify lifetime consequences of therapy with afatinib versus pem+cis, 
was amended to the Netherlands. The updated (2014) LUX-Lung 3 trial results and 
data from public sources were used to populate the model. Study outcomes were 
expressed in quality-adjusted life years (QALY), incremental cost-utility ratios (ICUR) 
and net monetary benefits (NMB). The analyses were conducted from health care and 
societal perspectives. Uncertainty assessment was performed using one-way and 
probabilistic sensitivity analyses (PSA). Results: Metastatic lung adenocarcinoma 
patients with common EGFR mutations (89%) had higher overall survival when treated 
with afatinib compared to pem+cis (HR: 0.78, p= 0.10). The corresponding base-case 
ICUR was < € 20,000/QALY gained. For the subgroup of patients harboring DEL19 muta-
tions (49%), treatment with afatinib resulted in cost-savings. Although NMB calcula-
tions were favorable for the genotype-directed therapy, inclusion of the entire patient 
population (all EGFR mutations) resulted in higher incremental costs. PSA results of 
lung adenocarcinoma patients with common EGFR mutations showed that afatinib 
is > 95% cost-effective compared to pem+cis at a € 80,000 threshold. cOnclusiOns: 
This study shows that genotype-directed therapy with afatinib improved survival in 
metastatic lung adenocarcinoma and translated itself as value-for-money, particu-
larly for the DEL19 subgroup, in the Netherlands. Further research is encouraged to 
compare afatinib with reversible EGFR inhibitors in this setting.
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Objectives: To assess the cost–utility of erythropoiesis-stimulating agents (ESAs) 
in conjunction with red blood cell transfusions (RBCTs) in patients with cancer-
treatment induced anaemia (CIA). MethOds: A cost–utility analysis from an NHS 
and personal social services perspective was conducted by developing an ad hoc 
economic model. A lifetime time horizon was used and outcomes were discounted 
at 3.5% per annum. All ESAs were assumed to have the same clinical effective-
ness. Haemoglobin (Hb) levels were assumed to drive health-related quality of life 
(HRQoL), with haemoglobin linearly mapped to utility. This was used to calculate 
lower than that with Herceptin-IV in the management of patients with HER2+ EBC 
and MBC. Hence, the substitution of Herceptin-IV with Herceptin-SC can produce 
valuable savings for the Greek health care system, especially in the current eco-
nomic environment where hospitals’ pharmaceutical budget has significantly been 
reduced.
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Objectives: Due to increasing costs in cancer management, there is a crescent 
need to rationally allocate resources in health care systems. Recently, a head-to-
head phase III study (CALGB80405) showed no significant difference in OS and PFS 
for first line (1L) mCRC in KRAS wild-type (wt) patients amongst bevacizumab (Bev) 
and cetuximab (Cet) – the most commonly used biologics in this setting. Since 
benefit of both drugs is comparable, the aim of the study was comparing treatment 
costs of Bev vs. Cet in 1L KRAS wt mCRC. MethOds: A cost-minimization analysis 
was conducted under payer perspective in Brazilian Supplementary Healthcare 
System. Backbone chemotherapy regimens (mFOLFOX6 and FOLFIRI) were based 
on CALGB80405 trial. Direct medical costs regarding drug acquisition, material and 
procedures/service fees were included. Adverse events management costs were 
excluded. The resource usage data was taken from the literature and drug labels. 
Costs were taken from CMED price list and UNIMED reimbursement lists. A uni-
variate sensitivity analysis was conducted varying parameters from ±20% range. 
Results were reported in Brazilian Reais (BRL). Results: The average monthly 
cost per patient was lower with Bev: BRL23’945 (Bev+mFOLFOX6) vs. BRL30’017 
(Cet+mFOLFOX6) – reduction of 20.2% - and BRL23’008 (Bev+FOLFIRI) vs. BRL29’075 
(Cet+FOLFIRI) – reduction of 20.9%. Average monthly cost per patient according to 
mFOLFOX6/FOLFIRI usage proportion reported on CALGB80405 was BRL23’699 (Bev) 
and BRL29’766 (Cet); considering PFS data presented in the trial, the average total 
treatment cost was estimated as BRL256’899 (Bev) and BRL311’060 (Cet). The sensi-
tivity analysis showed that model was more influenced by Cet price, Bev price and 
patient height. cOnclusiOns: Bev is a cost-saving choice for 1L KRAS wt mCRC 
in combination with chemotherapy, potentially achieving around 20% of reduction 
in monthly direct treatment costs compared to Cet, mainly because of Cet higher 
total acquisition costs and weekly administration schedule, resulting in additional 
resource consumption.
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Objectives: To analyze the economic impact of the incorporation of trastu-
zumab subcutaneous (TSC) in a University Hospital according to real data of our 
patients. MethOds: Retrospective cost minimization study that included patients 
diagnosed with breast cancer treated with trastuzumab intravenous (TIV) from 
april 2013 to april 2014. The demographic data of the patients (age and weight) 
and antineoplastic treatments used were obtained from the computer program 
Hospiwin®. An economic model was developed in Excel® data base, based on the 
dose used in previous clinical trials: IV loading dose of 8mg/kg and after 6mg/kg/3 
weeks and SC fixed dose of 600 mg/3 weeks. The time horizon was one year and 
the perspective of medical leadership of the hospital was used. The Spain cost of 
TSC is not aproved yet. Two posibilities was analyzed: The cost of filing 600mg of 
TSC equal to the cost of a 68kg patient with TIV (situation A) and the cost of a 63kg 
patient with TIV (situation B). A sensitivity analisys included the cost of using an 
oncology chair (168€ /treatment) was performed. Results: During the study period 
371 patients were treated for breast cancer. Of these 75 were treated with TIV (20.2%), 
with an average weight of 71.5 kg (SD= 17.1) and a cost of 990,996.88€ /per year. If 
all patients had been treated with TSC: Situation A the total spending would be 
829,965.4€ ; situation B the total spending would be 768,938.5€ . So the savings would 
be 161,031.4€ (19.4%) and 222,058.3€ (28.8%) respectively. If the cost of oncology 
chair (not necessary for the TSC) it´s included, the savings would be 253,549.4€ and 
314,576.3 respectively. cOnclusiOns: In this study we wanted to show how TSC 
saved costs in all of the situations analyzed. The TSC is a therapeutic innovation 
that helps promote the systems health´s sustainability.
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Objectives: To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs 
capecitabine, for advanced colorectal cancer (CRC) in adult patients. MethOds: 
Indirect comparison and network meta-analysis of clinical efficacy and safety of 
tegafur vs capecitabine and tegafur + calcium folinate vs capecitabine were per-
formed. Cost-minimization analysis (CMA) with calculation of cost minimization 
difference was used for economic evaluation of studied drugs. Results: There 
was no statistically significant difference in the full and partial objective tumor 
response between oral tegafur (both in monotherapy or in combination with calcium 
folinate) and capecitabine for advanced CRC treatment in an indirect comparison 
and network meta-analysis. Capecitabine vs tegafur + calcium folinate has less 
3-4th grade stomatitis but there was no difference in the incidence of diarrhea and 
3-4th grade nausea/vomiting. There was no difference in safety between tegafur 
